290 related articles for article (PubMed ID: 25136070)
21. Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva.
Takahashi M; Katagiri T; Furuya H; Hohjoh H
Gene Ther; 2012 Jul; 19(7):781-5. PubMed ID: 22130450
[TBL] [Abstract][Full Text] [Related]
22. Variable signaling activity by FOP ACVR1 mutations.
Haupt J; Xu M; Shore EM
Bone; 2018 Apr; 109():232-240. PubMed ID: 29097342
[TBL] [Abstract][Full Text] [Related]
23. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
[TBL] [Abstract][Full Text] [Related]
24. Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():497-502. PubMed ID: 30171563
[TBL] [Abstract][Full Text] [Related]
25. Genetic abnormalities in fibrodysplasia ossificans progressiva.
Miao J; Zhang C; Wu S; Peng Z; Tania M
Genes Genet Syst; 2012; 87(4):213-9. PubMed ID: 23229308
[TBL] [Abstract][Full Text] [Related]
26. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN
Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933
[TBL] [Abstract][Full Text] [Related]
27. ACVR1 (587T>C) mutation in a variant form of fibrodysplasia ossificans progressiva: second report.
Nakahara Y; Katagiri T; Ogata N; Haga N
Am J Med Genet A; 2014 Jan; 164A(1):220-4. PubMed ID: 24259422
[TBL] [Abstract][Full Text] [Related]
28. Identification of the Identical Human Mutation in
Casal ML; Engiles JB; Zakošek Pipan M; Berkowitz A; Porat-Mosenco Y; Mai W; Wurzburg K; Xu MQ; Allen R; ODonnell PA; Henthorn PS; Thompson K; Shore EM
Vet Pathol; 2019 Jul; 56(4):614-618. PubMed ID: 31007133
[TBL] [Abstract][Full Text] [Related]
29. ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant.
Haupt J; Deichsel A; Stange K; Ast C; Bocciardi R; Ravazzolo R; Di Rocco M; Ferrari P; Landi A; Kaplan FS; Shore EM; Reissner C; Seemann P
Hum Mol Genet; 2014 Oct; 23(20):5364-77. PubMed ID: 24852373
[TBL] [Abstract][Full Text] [Related]
30. Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.
Whyte MP; Wenkert D; Demertzis JL; DiCarlo EF; Westenberg E; Mumm S
J Bone Miner Res; 2012 Mar; 27(3):729-37. PubMed ID: 22131272
[TBL] [Abstract][Full Text] [Related]
31. Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva.
Towler OW; Shore EM; Kaplan FS
Bone; 2020 Jan; 130():115116. PubMed ID: 31655222
[TBL] [Abstract][Full Text] [Related]
32. The Fibrodysplasia Ossificans Progressiva (FOP) mutation p.R206H in ACVR1 confers an altered ligand response.
Hildebrand L; Stange K; Deichsel A; Gossen M; Seemann P
Cell Signal; 2017 Jan; 29():23-30. PubMed ID: 27713089
[TBL] [Abstract][Full Text] [Related]
33. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Mohedas AH; Wang Y; Sanvitale CE; Canning P; Choi S; Xing X; Bullock AN; Cuny GD; Yu PB
J Med Chem; 2014 Oct; 57(19):7900-15. PubMed ID: 25101911
[TBL] [Abstract][Full Text] [Related]
34. Mutations of the noggin (NOG) and of the activin A type I receptor (ACVR1) genes in a series of twenty-seven French fibrodysplasia ossificans progressiva (FOP) patients.
Lucotte G; Houzet A; Hubans C; Lagarde JP; Lenoir G
Genet Couns; 2009; 20(1):53-62. PubMed ID: 19400542
[TBL] [Abstract][Full Text] [Related]
35. Patients with ACVR1
Kou S; De Cunto C; Baujat G; Wentworth KL; Grogan DR; Brown MA; Di Rocco M; Keen R; Al Mukaddam M; le Quan Sang KH; Masharani U; Kaplan FS; Pignolo RJ; Hsiao EC
Orphanet J Rare Dis; 2020 Jul; 15(1):193. PubMed ID: 32727600
[TBL] [Abstract][Full Text] [Related]
36. An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva.
Chakkalakal SA; Zhang D; Culbert AL; Convente MR; Caron RJ; Wright AC; Maidment AD; Kaplan FS; Shore EM
J Bone Miner Res; 2012 Aug; 27(8):1746-56. PubMed ID: 22508565
[TBL] [Abstract][Full Text] [Related]
37. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.
Hino K; Ikeya M; Horigome K; Matsumoto Y; Ebise H; Nishio M; Sekiguchi K; Shibata M; Nagata S; Matsuda S; Toguchida J
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15438-43. PubMed ID: 26621707
[TBL] [Abstract][Full Text] [Related]
38. Fibrodysplasia ossificans progressiva.
Kaplan FS; Le Merrer M; Glaser DL; Pignolo RJ; Goldsby RE; Kitterman JA; Groppe J; Shore EM
Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):191-205. PubMed ID: 18328989
[TBL] [Abstract][Full Text] [Related]
39. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
[TBL] [Abstract][Full Text] [Related]
40. Fibrodysplasia ossificans progressiva: clinical and genetic aspects.
Pignolo RJ; Shore EM; Kaplan FS
Orphanet J Rare Dis; 2011 Dec; 6():80. PubMed ID: 22133093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
